NCT05315336View on ClinicalTrials.gov

L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
DRUG

L-DEP and PD-1 antibody

Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.

Trial Locations (1)

Unknown

Beijing Friendship Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Friendship Hospital

OTHER

NCT05315336 - L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH | Biotech Hunter | Biotech Hunter